Cartoon Illustrating “The NIH and U.S. Healthcare in Crisis” Published
| | | | | | | | | | | | | | | | | | | | | | | | | |

Cartoon Illustrating “The NIH and U.S. Healthcare in Crisis” Published

On Apr. 21, 2025, LifeScienceHistory.com published the cartoon: “The National Institutes of Health (NIH) and U.S. Healthcare in…

HHS starts layoffs of thousands of workers across its agencies
| | | | | | | | | | | | | | | | | | | | | |

HHS starts layoffs of thousands of workers across its agencies

On Apr. 1, 2025, layoff notices began arriving for thousands of employees of the sprawling U.S. Department of…

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis
| | |

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis

On Mar. 20, 2025, Alnylam Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) approval of the supplemental…

FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
| | | | | |

FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness

On Feb. 4, 2025, Genentech announced that the U.S. Food and Drug Administration (FDA) had approved Susvimo® (ranibizumab…

FDA approves Ozempic® (semaglutide) as only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and CKD
| | | |

FDA approves Ozempic® (semaglutide) as only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and CKD

On Jan. 28, 2025, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved Ozempic® to…

U.S. FDA Approved Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
| | | | | |

U.S. FDA Approved Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer

On Dec. 20, 2024, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved BRAFTOVI® (encorafenib)…

FDA approved Alhemo® injection as once-daily prophylactic treatment to reduce frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B
| | | | |

FDA approved Alhemo® injection as once-daily prophylactic treatment to reduce frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B

On Dec. 20, 2024, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Alhemo®…